1Gaist D,Rodriguez LA,Huerta C,et al.Lipid-lowering drugs and risk of myopathy:a populat-ion based follow-up study.Epidemiology,2001,12:565-569.
2García Rodríguez LA,Herings R.Use of multiple international healthcare databases for the detection of rare drug-associated outcomes:a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.Pharmacoepidemiol Drug Saf,2010,19:1218-1224.
3de Lemos JA,Blazing MA,Wiviott SD,et al.Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes:phase Z of the A to Z trail.trial.JAMA,2004,292:1307-1316.
4Graham DJ,Staffa JA,Shatin D,et al.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.JAMA,2004,292:2585-2590.
5Armitage J.The safety of statins in clinical practice.Lancet,2007,370:1781-1790.
7Vermes A,Vermes I.Genetic polymorphisms in cytochrome P450 enzymes:effect on efficacy and tolerability of HMG-CoA reductase inhibitors.Am J Cardiovasc Drugs,2004,4:247-255.
8Kelly P,Vasu S,Getato M,et al.Coenzyme Q10 improves myopathic pain in statin treated patients.J Am Coll Cardiol,2005,45:3A.
9Vladutiu R,Isackson P,Peltier W,et al.Genetic risk factors and metabolic abnormalities associated with lipid lowering therapies.Muscle Nerve,2006,34:153-162.
10Oh J,Ban MR,Miskie BA,et al.Genetic determinants of statin intolerance.Lipids Health Dis,2007,6:7.
5Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or low- er-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) :a multieen- tre randomised controlled trial[J]. Lancet ,2003 ;361 ( 9364 ) : 1149-58.
6Poll A. Atorvastatin: pharmacological characteristics and lipid-lowering effects[ J]. Drugs,2007 ;67( Suppl 1 ) :3-15.
7Rubba P. Effects of atorvastatin on the different phases of athemgenesis [ J]. Drugs ,2007 ;67 ( Suppl 1 ) : 17-27.
8Chung M, Calcagni A, Glue P, et al. Bioavailability of amlodipine besy- late/atorvastatin calcium combination talett [J]. J Clin Pharmaco1,2006 ; 46(9) :1030-7.
9Chung M, Calcagni A, Glue P, et al. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet [J]. J Clin Pharmaco1,2006 ;46 ( 10 ) : 1212-6.
10Whitfield LR, Stern RH,Sedman AJ,et al. Effect of food on the pharma- codynamics and pharmacokinetics of atorvastatin, an inhibitor of HMG- CoA reductase [ J ]. Eur J Drug Metab Pharmacokinet, 2000 ; 25 ( 2 ) : 97- 101.
